Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Curing myeloma at last: defining criteria and providing the evidence.

Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J.

Blood. 2014 Nov 13;124(20):3043-51. doi: 10.1182/blood-2014-07-552059. Epub 2014 Oct 7.

2.

European perspective on multiple myeloma treatment strategies in 2014.

Ludwig H, Sonneveld P, Davies F, Bladé J, Boccadoro M, Cavo M, Morgan G, de la Rubia J, Delforge M, Dimopoulos M, Einsele H, Facon T, Goldschmidt H, Moreau P, Nahi H, Plesner T, San-Miguel J, Hajek R, Sondergeld P, Palumbo A.

Oncologist. 2014 Aug;19(8):829-44. doi: 10.1634/theoncologist.2014-0042. Epub 2014 Jul 25. Review.

3.

Curability of multiple myeloma.

Alexanian R, Delasalle K, Wang M, Thomas S, Weber D.

Bone Marrow Res. 2012;2012:916479. doi: 10.1155/2012/916479. Epub 2012 May 23.

4.

European perspective on multiple myeloma treatment strategies: update following recent congresses.

Ludwig H, Avet-Loiseau H, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Davies F, de la Rubia J, Delimpasi S, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Hess U, Mellqvist UH, Moreau P, San-Miguel J, Sondergeld P, Sonneveld P, Udvardy M, Palumbo A.

Oncologist. 2012;17(5):592-606. doi: 10.1634/theoncologist.2011-0391. Epub 2012 May 9. Review. Erratum in: Oncologist. 2012;17(7):1005.

5.

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.

Hoering A, Crowley J, Shaughnessy JD Jr, Hollmig K, Alsayed Y, Szymonifka J, Waheed S, Nair B, van Rhee F, Anaissie E, Barlogie B.

Blood. 2009 Aug 13;114(7):1299-305. doi: 10.1182/blood-2009-03-211953. Epub 2009 Jun 10.

6.

A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97.

Vesole DH, Zhang L, Flomenberg N, Greipp PR, Lazarus HM, Huff CA; ECOG Myeloma and BMT Committees.

Biol Blood Marrow Transplant. 2009 Jan;15(1):83-91. doi: 10.1016/j.bbmt.2008.10.030. Erratum in: Biol Blood Marrow Transplant. 2009 Oct;15(10):1346. Huff, Carol A [added].

7.

Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.

Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, Storrie B, Mulder A, Shaughnessy JD Jr, Barlogie B, van Rhee F.

Blood. 2008 Feb 1;111(3):1309-17. Epub 2007 Oct 18.

8.

Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.

Georges GE, Maris MB, Maloney DG, Sandmaier BM, Sorror ML, Shizuru JA, Lange T, Agura ED, Bruno B, McSweeney PA, Pulsipher MA, Chauncey TR, Mielcarek M, Storer BE, Storb R.

Biol Blood Marrow Transplant. 2007 Apr;13(4):423-32. Epub 2007 Feb 1.

Items per page

Supplemental Content

Write to the Help Desk